Cargando…

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature

Radiation recall dermatitis is an inflammatory reaction of the skin that may infrequently occur in areas of the skin that have been previously treated with radiation therapy. This is thought to be due to a triggering agent administered after radiation therapy which leads to an acute inflammatory rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandhu, Michael, Ashok Kumar, Prashanth, Deck, Jared, Zerdan, Maroun Bou, Lacombe, Michael, Sivapiragasam, Abirami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134185/
https://www.ncbi.nlm.nih.gov/pubmed/37096743
http://dx.doi.org/10.1177/23247096231168114
_version_ 1785031705841631232
author Sandhu, Michael
Ashok Kumar, Prashanth
Deck, Jared
Zerdan, Maroun Bou
Lacombe, Michael
Sivapiragasam, Abirami
author_facet Sandhu, Michael
Ashok Kumar, Prashanth
Deck, Jared
Zerdan, Maroun Bou
Lacombe, Michael
Sivapiragasam, Abirami
author_sort Sandhu, Michael
collection PubMed
description Radiation recall dermatitis is an inflammatory reaction of the skin that may infrequently occur in areas of the skin that have been previously treated with radiation therapy. This is thought to be due to a triggering agent administered after radiation therapy which leads to an acute inflammatory reaction, manifesting as a skin rash. We present the case of a 58-year-old male with recurrent invasive squamous cell carcinoma of the tongue, previously treated with chemotherapy and radiation therapy, who presented with progression of his disease. He was treated with pembrolizumab and subsequently developed a new-onset facial rash over the previously treated radiation field. The distribution of the rash was suggestive of radiation recall dermatitis. A biopsy showed dermal necrosis without evidence of dermatitis, vasculitis, or infectious process. This case highlights the incidence of a rare complication of immune checkpoint inhibitor therapy and emphasizes the need for careful monitoring for radiation recall dermatitis.
format Online
Article
Text
id pubmed-10134185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101341852023-04-28 Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature Sandhu, Michael Ashok Kumar, Prashanth Deck, Jared Zerdan, Maroun Bou Lacombe, Michael Sivapiragasam, Abirami J Investig Med High Impact Case Rep Case Report Radiation recall dermatitis is an inflammatory reaction of the skin that may infrequently occur in areas of the skin that have been previously treated with radiation therapy. This is thought to be due to a triggering agent administered after radiation therapy which leads to an acute inflammatory reaction, manifesting as a skin rash. We present the case of a 58-year-old male with recurrent invasive squamous cell carcinoma of the tongue, previously treated with chemotherapy and radiation therapy, who presented with progression of his disease. He was treated with pembrolizumab and subsequently developed a new-onset facial rash over the previously treated radiation field. The distribution of the rash was suggestive of radiation recall dermatitis. A biopsy showed dermal necrosis without evidence of dermatitis, vasculitis, or infectious process. This case highlights the incidence of a rare complication of immune checkpoint inhibitor therapy and emphasizes the need for careful monitoring for radiation recall dermatitis. SAGE Publications 2023-04-25 /pmc/articles/PMC10134185/ /pubmed/37096743 http://dx.doi.org/10.1177/23247096231168114 Text en © 2023 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Sandhu, Michael
Ashok Kumar, Prashanth
Deck, Jared
Zerdan, Maroun Bou
Lacombe, Michael
Sivapiragasam, Abirami
Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title_full Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title_fullStr Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title_full_unstemmed Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title_short Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
title_sort radiation recall dermatitis following treatment with pembrolizumab: a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134185/
https://www.ncbi.nlm.nih.gov/pubmed/37096743
http://dx.doi.org/10.1177/23247096231168114
work_keys_str_mv AT sandhumichael radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature
AT ashokkumarprashanth radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature
AT deckjared radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature
AT zerdanmarounbou radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature
AT lacombemichael radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature
AT sivapiragasamabirami radiationrecalldermatitisfollowingtreatmentwithpembrolizumabacasereportandreviewoftheliterature